| Field | Specification |
|---|---|
| Alternative names | Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C5H12N2O8P2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Zoledronic acid monohydrate, also known as Zoledronate monohydrate, CGP 42446 monohydrate, CGP42446A monohydrate, or ZOL 446 monohydrate, is a third-generation bisphosphonate (BP) with potent anti-resorptive activity. It inhibits the differentiation and apoptosis of osteoclasts and also has anti-cancer effects[1]. It is supplied as a white to off-white solid (C5H12N2O8P2, MW 290.10) at 99.58% purity.
Physical & Chemical Properties
| CAS Number | 165800-06-6 |
|---|---|
| Molecular Formula | C5H12N2O8P2 |
| Molecular Weight | 290.10 g/mol |
| Purity | 99.58% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1.[H]O[H] |
| Signaling Pathway | Apoptosis; Autophagy; Anti-infection |
| Solubility | In Vitro: H2O: 28.57 mg/mL (98.48 mM; Requires sonication and adjust pH to 9 with 1 M NaOH) H2O: 14.29 mg/mL (49.26 mM; Requires sonication and adjust pH to 8 with NaOH) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | 28.57 mg/mL (98.48 mM) | requires sonication and adjust pH to 9 with 1 M NaOH |
| H2O | 14.29 mg/mL (49.26 mM) | requires sonication and adjust pH to 8 with NaOH |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
In Vivo
Choose the formulation that suits the animal model and route of administration. Percentages are volume ratios of the final working solution. Prepare the working solution fresh on the day of dosing; if precipitation or phase separation occurs, gentle warming or sonication can help.
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 1
| Composition | PBS |
|---|---|
| Result | 3.33 mg/mL (11.48 mM); clear solution; requires sonication and warming and heat to 60°C |
Data provided by the manufacturer.
In Vitro
In osteocyte-like MLO-Y4 cells, Zoledronic Acid monohydrate (0.1-1 μM; 48 hours) raises mRNA expression of receptor activator of nuclear factor kB ligand (RANKL) and sclerostin[2]. Zoledronic Acid monohydrate increases expression of an osteoclastogenesis supporting factor in MLO-Y4 cells[2]. In MLO-Y4 cells, Zoledronic Acid monohydrate enhances RANKL expression via the IL-6/ JAK2/STAT3 pathway[2]. Zoledronic Acid monohydrate inhibits osteoclast differentiation and function by regulating the NF-κB and JNK signalling pathways[3]. In MC3T3-E1 cells, viability is markedly reduced by Zoledronic Acid monohydrate (10-100 μM; 1-7 days)[4]. Apoptosis is induced in MC3T3-E1 cells by Zoledronic Acid monohydrate (10-100 μM; 1-7 days)[4]. Zoledronic Acid monohydrate (10-100 μM; 4 days) inhibits cell viability by inducing apoptosis[4]. At concentrations <1 μM, Zoledronic Acid monohydrate has inhibitory effects on differentiation and maturation of MC3T3-E1 cells[4].
Cell Viability Assay[4]
| Cell Line | MC3T3-E1 cells |
|---|---|
| Concentration | 0.02 μM, 0.1 μM, 1 μM, 10 μM, 100 μM |
| Incubation Time | 1 day, 3 days, 5 days, 7 days |
| Result | Reduced cells viability at 10 μM and 100 μM. |
Apoptosis Analysis[4]
| Cell Line | MC3T3-E1 cells |
|---|---|
| Concentration | 0.02 μM, 0.1 μM, 1 μM, 10 μM, 100 μM |
| Incubation Time | 1 days, 4 days, 7 days |
| Result | Increased the number of early apoptotic cells and late apoptotic or necrotic cells at dose-dependent and time-dependent (high concentrations). |
Western Blot Analysis[4]
| Cell Line | MC3T3-E1 cells |
|---|---|
| Concentration | 0.02 μM, 0.1 μM, 1 μM, 10 μM, 100 μM |
| Incubation Time | 4 days |
| Result | Down-regulated the protein level of inactive caspase-3 and up-regulated the protein level of active caspase-3 at the concentrations of 10 and 100 μM. |
In Vivo
Zoledronic Acid monohydrate given at 0.05 mg/kg (i.p., weekly, for 3 weeks) raises bone mineral density and content[5]. At 0.5-1 mg/kg (i.p., weekly, for 3 weeks), Zoledronic Acid monohydrate suppresses the function of both osteoclasts and osteoblasts as well as bone remodeling in vivo, which interferes with bone mechanical properties[5].
| Animal Model | Five-week-old C57BL6 mice[5] |
|---|---|
| Dosage | 0.05 mg/kg, 0.5 mg/kg, 1 mg/kg |
| Administration | Intraperitoneal injection, weekly, for 3 weeks |
| Result | Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Chemical engineering of γδ T cells with cancer cell-targeting antibodies for enhanced tumor immunotherapy. Natl Sci Rev 2025 Jun 27;12(8):nwaf256. PMID: 40842867
Osteocyte mitochondria regulate angiogenesis of transcortical vessels. Nat Commun 2024 Mar 21;15(1):2529. PMID: 38514612
A Dual-Targeted Metal-Organic Framework Based Nanoplatform for the Treatment of Rheumatoid Arthritis by Restoring the Macrophage Niche. ACS Nano 2023 Jul 25;17(14):13917-13937. PMID: 37429012
Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. Gut Microbes 2023 Dec;15(2):2249143. PMID: 37635362
Matrix micro/nano-topography drives oncogenic signaling and drug response in a 3D osteosarcoma model. J Nanobiotechnology 2026 Mar 6;24(1):345. PMID: 41787498
Impaired function of Vγ9Vδ2 T cells in frail elderly. Immun Ageing 2026 Jan 16;23(1):7. PMID: 41546035
Biomaterial-Based Lymphangiogenesis-Enhanced Therapeutic Strategy for Robustly-Integrated Medication-Related Osteonecrosis of Jaw Prevention. ACS Appl Mater Interfaces 2025 Jun 25;17(25):36315-36333. PMID: 40518597
Chem Eng J Adv. 2026 Feb 16.
Aerobic exercise prevents renal osteodystrophy via irisin-activated osteoblasts. JCI Insight 2025 Jan 30;10(5):e184468. PMID: 39883525
Innovative medicinal chemistry strategies for enhancing drug solubility. Eur J Med Chem 2024 Dec 5:279:116842. PMID: 39260319
